Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity Pharmaceutical TechnologyKOLs note that CagriSema could cannibalise semaglutide's market share in obesity due to its improved weight loss and HbA1c reduction efficacy.Clinical DataMetabolic & GLP-1Read full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalryNext: AZ claims another win for Imfinzi in frontline liver cancer Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
